Welcome to our dedicated page for Iridex news (Ticker: IRIX), a resource for investors and traders seeking the latest updates and insights on Iridex stock.
Iridex Corporation develops, manufactures, and markets laser-based medical systems, delivery devices, procedure probes, accessories, and consumable instrumentation for ophthalmology. Its products support treatment of glaucoma, diabetic macular edema, and other retinal diseases, with proprietary MicroPulse® technology used across parts of its portfolio.
Iridex news commonly covers quarterly and annual financial results, business updates, product-family activity for systems such as Cyclo G6®, retina laser platforms including PASCAL®, IQ 532®, IQ 577®, and OcuLight® TX, and clinical literature involving MicroPulse transscleral laser therapy. Company updates also address commercial partnerships, U.S. direct sales, international distributor activity, operational efficiency measures, and Nasdaq listing-status matters.
IRIDEX Corporation (Nasdaq: IRIX) reported third-quarter financial results for the period ending September 26, 2020. Total revenue was $8.8 million, down 17% year-over-year but up 42% sequentially. The company sold 11,400 Cyclo G6 probes, marking a 6% increase from the prior year and a 44% increase from the previous quarter. However, sales of Cyclo G6 Glaucoma Laser Systems fell to 37 units from 82 a year ago due to COVID-related deferrals. The company ended the quarter with $11.9 million in cash and a reduced net loss of $1.7 million.
IRIDEX Corporation (Nasdaq: IRIX) announced its participation in the Stifel Virtual Healthcare Conference on November 17, 2020, at 4:40 pm ET. David I. Bruce, the CEO, will present, and interested individuals can access the live and archived webcast via the IRIDEX website.
IRIDEX specializes in laser-based medical systems for ophthalmology, notably using MicroPulse technology for treating conditions like glaucoma and diabetic macular edema. Its products are available in over 100 countries.
IRIDEX Corporation (Nasdaq: IRIX) will release its Q3 2020 financial results after trading hours on November 9, 2020. The management team will host a conference call at 2:00 p.m. PT to discuss the results. Interested investors can join via a dedicated phone line or through a live webcast available on the company’s website. IRIDEX is a leading developer of laser-based medical systems for the ophthalmology market, providing innovative treatments for conditions like glaucoma and diabetic macular edema through its proprietary MicroPulse® technology.
IRIDEX Corporation (Nasdaq: IRIX) reported a 40% decline in second-quarter revenues, totaling $6.2 million, compared to $10.4 million in the previous year. Despite a net loss of $2.8 million, the loss was contained due to cost control measures. Cyclo G6 product revenue fell 38.2% year-over-year. However, probe shipments rebounded, exceeding 80% of pre-COVID levels by June. Ending cash balance stood at $11.6 million, bolstered by a $2.5 million PPP loan. The company refrained from providing full-year guidance due to ongoing uncertainties.
IRIDEX Corporation (Nasdaq: IRIX) will announce its second quarter 2020 financial results after trading on August 6, 2020. Management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET, with dial-in options for domestic (844-707-0665) and international callers (703-326-3030), using conference ID: 6486158. A live and archived webcast will be available on the company’s website. IRIDEX specializes in laser-based medical systems for ophthalmology, utilizing its MicroPulse® technology to address conditions like glaucoma and diabetic macular edema.
Summary not available.